2026 EHA | Over 40 Orelabrutinib Studies Presented, Including First Clinical Data from Europe and US TN CLL/SLL Patients
BEIJING, June 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
Poster presentations from ongoing clinical trials of two core assets, olverembatinib and…
UFC GYM India Announces the Grand Opening of Its Second Premium Fitness Club in Jaipur
This 20,000 sq. ft. facility will redefine fitness standards in Jagatpura, which…
Modat adds Passive DNS to its Platform Magnify, Connecting Every Signal in a Single Investigation Graph
THE HAGUE, the Netherlands, June 14, 2026 (GLOBE NEWSWIRE) -- Modat today…
XM Announces Enhanced Trading Conditions and Opportunities for Global Traders – Featuring Partner Code 274PQ
TORONTO, June 14, 2026 (GLOBE NEWSWIRE) -- As participation in online financial…
![FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement](https://i0.wp.com/ml.globenewswire.com/Resource/Download/f5c162c3-7ed8-4fb7-b515-f4d8f819e583?w=420&resize=420,280&ssl=1 "FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement")
FemiCore [Exclusive Report 2026] Femi Core Warning Why Thousands of Women Are Suddenly Talking About This Bladder Health Supplement
New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- In a…
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating…
As the Lights Fade, Vivid Sydney 2026 Leaves the City Glowing
Images HERESYDNEY, June 13, 2026 /PRNewswire/ -- Off the back of 23…
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Achieved 100% ORR and 83.3% CR rate at dose level 2 following…
KFSH Highlights Human-Centered AI as a Path to Better Care at HLTH Europe 2026
RIYADH, Saudi Arabia, June 14, 2026 (GLOBE NEWSWIRE) -- At HLTH Europe…
